Director/PDMR Shareholding

RNS Number : 3011Q
Oxford Biomedica PLC
28 November 2016







Director Dealings / Market Share Purchase


Oxford, UK - 28 November 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Friday, 25 November 2016, acquired ordinary shares in the Group as set out below, under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.


Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price.







Interest after purchase

Director / PDMR


Price per share (p)

Number of Ordinary Shares acquired

Number of Ordinary Shares

% of total

issued share capital

Dr Lorenzo Tallarigo







The issued share capital of the Group is 3,087,953,461 ordinary 1p shares.                   






For further information, please contact:



Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer


Tel: +44 (0)1865 783 000


Financial and corporate communications enquiries:

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton


Tel: +44 (0)20 3709 5700



Notes for editors


About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at


This information is provided by RNS
The company news service from the London Stock Exchange